Biodefense R&D: First Anthrax Vaccine Could Enter Phase II In 2004
This article was originally published in The Pink Sheet Daily
Executive Summary
An HHS contract is supporting the development of VaxGen's recombinant anthrax vaccine. Acambis/Baxter's second-generation smallpox vaccine ACAM-2000 is in Phase II.
You may also be interested in...
Anthrax Vaccine Is HHS' First Contract Award Under Project BioShield
VaxGen receives $877.5 mil. contract to supply 75 mil. doses of its recombinant protective antigen anthrax vaccine to the national stockpile within three years. The contract is contingent upon FDA clearing the vaccine for use under emergency conditions.
Anthrax Vaccine Is HHS' First Contract Award Under Project BioShield
VaxGen receives $877.5 mil. contract to supply 75 mil. doses of its recombinant protective antigen anthrax vaccine to the national stockpile within three years. The contract is contingent upon FDA clearing the vaccine for use under emergency conditions.
Mixed Smallpox Vaccine Stockpile Could Complicate Mass Vaccination, Bavarian Nordic Says
Smallpox vaccine candidate Imvamune has not demonstrated the potential for serious adverse events associated with Wyeth's Dryvax or Acambis/Baxter's ACAM-2000, VP-R&D Paul Chaplin, PhD, says in interview with "The Blue Sheet."